Navigation Links
EpiVax-Novozymes Tregitope-Albumin Fusion Moves 'Paradigm-Shifting' Treatment for Diabetes Closer to Clinical Trials
Date:2/12/2013

PROVIDENCE, R.I., Feb. 12, 2013 /PRNewswire/ -- EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering agent, albumin has excellent safety and pharmacokinetic profiles. Fusing Tregitopes to Novozymes' proven albumin-based half-life extension platform will create a safe and effective vehicle for the application of Tregitopes to multiple problems in the areas of autoimmunity, transplantation, and allergy.

(Logo: http://photos.prnewswire.com/prnh/20121116/NE15175LOGO )

Tregitopes, discovered by Anne De Groot and Bill Martin at EpiVax, are linear sequences of amino acids contained within the framework of monoclonal antibodies and immunoglobulin G; the original finding was published in the journal Blood in 2008. Since their discovery, EpiVax has compiled substantial evidence linking Tregitopes to the activation of natural regulatory T cells. By selectively activating these natural regulatory T cells, Tregitopes can dampen unwanted immune responses. Preliminary studies carried out by EpiVax and collaborators indicate that Tregitopes may be useful for inducing tolerance to transplants, protein drugs, and blood replacement therapies, as well as for the treatment of allergies. EpiVax believes Tregitopes may explain the effectiveness of intravenous immunoglobulin G (IVIG), widely utilized as an autoimmune treatment (a $4B annual market).

The initial disease target for Tregitope therapy with the albumin-Tregitope fusion will be Type 1 diabetes (T1D). Each year, more than 13,000 young people are diagnosed with T1D. Islet replacement therapy is in the experimental stage for individuals with advanced disease, and EpiVax believes the albumin-Tregitope fusion will facilitate this novel treatment for individuals in later stages of T1D.

Tregitopes act as a natural immune system "off switch" and have been shown in standard preclinical models to "reset" immune responses away from autoimmunity and towards tolerance. "Developing more specific therapies to promote tolerance … is a critical component of a comprehensive approach to T1D," said Julia L. Greenstein , Ph.D., VP of Cure Therapies for JDRF, whose previous funding helped EpiVax derive preliminary data to support recent NIH awards.  "[Tregitopes] may have the potential to reduce the harmful immune responses to the insulin-producing beta cells, thereby preserving the body's ability to make its own insulin." 

NIH SBIR grants coupled with private foundation funds have brought total pre-clinical funding for Tregitopes to more than $6M in the past 4 years.

FULL ARTICLE - http://bit.ly/EpiVaxNovoPR

Contact:
Anthony Marcello
1-401-272-2123
amarcello@epivax.com
www.epivax.com


'/>"/>
SOURCE EpiVax, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CareFusion Launches New Take-Apart Laparoscopic Scissors
2. CareFusion Reports First Half Fiscal 2013 Results
3. CareFusion Files Fiscal 2012 Form 10-K
4. B. Braun Smart Infusion Pump Technology Advances Patient Safety and Treatment Efficiency
5. Global Spinal Nonfusion Market to Grow to $1 Billion by 2017, Despite Challenges
6. Hospira and Q Core Medical Sign International Distribution Agreement for Sapphire Infusion System
7. CareFusion Launches New Preoperative Cleansing Program For In-Home Patient Use
8. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
9. Practice Fusion Announces Free EMR for iPad in Beta
10. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
11. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals ... the field of eating disorders, announces the opening of early registration for the ... at the Omni Resort at ChampionsGate. , The annual iaedp™ Symposium ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):